Scarica l'app Stockscreener
5.42
7.11%
0.36
Dopo l'orario di chiusura:
5.39
-0.03
-0.55%
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Measuring Aquestive Therapeutics Inc.’s beta against major indicesEarnings Summary Report & Capital Efficient Trading Techniques - Newser
Aquestive Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Aquestive Therapeutics: Expect Its Torrid Pace To Relax (Rating Downgrade) (NASDAQ:AQST) - Seeking Alpha
Is Aquestive Therapeutics Inc. stock good for income investorsJuly 2025 Volume & AI Enhanced Trading Alerts - خودرو بانک
What are Aquestive Therapeutics Inc.’s recent SEC filings showingEarnings Growth Summary & Long-Term Capital Growth Strategies - خودرو بانک
Is Aquestive Therapeutics Inc. stock a smart retirement pickWeekly Investment Summary & Capital Protection Trading Alerts - خودرو بانک
Can Aquestive Therapeutics Inc. grow without external fundingJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - خودرو بانک
Aquestive jumps as FDA says no AdCom for allergy therapy Anaphylm - MSN
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA - sharewise.com
Aquestive Therapeutics' Strategic Path to Anaphylm Approval and Market Capture - AInvest
Aquestive Therapeutics: No AdCom For Anaphylm Derisks January Approval Catalyst (AQST) - Seeking Alpha
Should you wait for a breakout in Aquestive Therapeutics Inc.Weekly Stock Analysis & Smart Investment Allocation Insights - Newser
News impact scoring models applied to Aquestive Therapeutics Inc.Share Buyback & Verified Entry Point Detection - Newser
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
Aquestive Therapeutics shares rise 2.17% premarket after FDA waives advisory committee meeting for Anaphylm. - AInvest
What Fibonacci levels say about Aquestive Therapeutics Inc. reboundTrade Analysis Report & Community Consensus Trade Signals - Newser
FDA won’t require advisory committee meeting for Aquestive’s anaphylaxis film - Investing.com Canada
Aquestive gains as allergy therapy undergoes FDA review - MSN
Evaluating Aquestive Therapeutics Inc. with trendline analysis2025 Market Trends & Low Drawdown Investment Ideas - Newser
Why Is Aquestive Therapeutics Stock Soaring Thursday?Aquestive Therapeutics (NASDAQ:AQST) - Benzinga
Aquestive Therapeutics Shares Rise, FDA Forgos Meeting on Anaphylm - MarketScreener
Aquestive Therapeutics at Cantor Global Healthcare Conference: Strategic Moves for ANNAFILM - Investing.com Canada
Aquestive Therapeutics shares surge 21.39% intraday after FDA waives advisory committee meeting for Anaphylm, a device-free, sublingual epinephrine film for severe allergic reactions. - AInvest
Analyzing recovery setups for Aquestive Therapeutics Inc. investorsJuly 2025 WrapUp & Verified Chart Pattern Trade Signals - Newser
Aquestive Therapeutics, Inc. Announces FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm?? - MarketScreener
Aquestive Therapeutics Shares Soar 20% on FDA Approval Pathway - AInvest
Aquestive says no FDA AdCom for Anaphylm (AQST:NASDAQ) - Seeking Alpha
Aquestive climbs after US FDA says no advisory panel needed for epinephrine film - TradingView
Aquestive Therapeutics Announces that FDA Will Not Require - GlobeNewswire
First-Ever Needle-Free Epinephrine Film: Aquestive's Anaphylm Clears Key FDA Hurdle Without Committee Review - Stock Titan
Will Aquestive Therapeutics Inc. stock recover after recent dropMarket Growth Summary & Risk Managed Trade Strategies - Newser
How moving averages guide Aquestive Therapeutics Inc. tradingJuly 2025 Institutional & Stepwise Swing Trade Plans - Newser
Published on: 2025-09-03 22:42:37 - Newser
Can Aquestive Therapeutics Inc. ride the EV waveSell Signal & Intraday High Probability Alerts - خودرو بانک
What momentum shifts mean for Aquestive Therapeutics Inc.Weekly Trend Summary & Safe Capital Growth Plans - Newser
Risk adjusted return profile for Aquestive Therapeutics Inc. analyzed2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Live market analysis of Aquestive Therapeutics Inc.Gold Moves & Accurate Intraday Trade Tips - Newser
Is Aquestive Therapeutics Inc. forming a reversal patternM&A Rumor & Short-Term High Return Strategies - Newser
Aquestive Therapeutics Inc. stock prediction for this week2025 Historical Comparison & Accurate Intraday Trade Tips - Newser
Regression analysis insights on Aquestive Therapeutics Inc. performanceWeekly Loss Report & Verified Momentum Watchlists - Newser
Momentum divergence signals in Aquestive Therapeutics Inc. chart - Newser
Can Aquestive Therapeutics Inc. continue delivering strong returns2025 Big Picture & AI Powered Market Entry Ideas - khodrobank.com
Is Aquestive Therapeutics Inc. stock entering bullish territoryJuly 2025 Outlook & AI Optimized Trade Strategies - Newser
Aquestive Therapeutics Inc. recovery potential after sell offPortfolio Gains Report & Risk Managed Investment Strategies - Newser
Can Aquestive Therapeutics Inc. hit a new high this monthEarnings Growth Report & Safe Capital Growth Tips - Newser
Comparing Aquestive Therapeutics Inc. in custom built stock radarsJuly 2025 Big Picture & Low Drawdown Investment Ideas - Newser
3.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):